CJC-1295 DAC 5mg

CJC-1295 DAC is a synthetic GHRH analog that binds to receptors on pituitary somatotroph cells, triggering a signaling cascade that increases growth hormone and downstream IGF-1 production. The DAC (Drug Affinity Complex) modification extends its half-life by binding to albumin in the bloodstream.

The Drug Affinity Complex extends the half-life to approximately eight days, allowing sustained elevation of growth hormone markers with less frequent administration than short-acting secretagogues.

The version without DAC (also known as Mod GRF 1-29) has a half-life of only minutes and typically requires multiple daily administrations. The DAC version binds plasma albumin, creating a depot effect that can sustain activity for more than a week.

This product is intended for qualified researchers and experienced professionals familiar with peptide handling, reconstitution, and endocrine physiology. It is not designed for inexperienced laboratory users.

In research settings, peak growth hormone expression is typically observed within two hours of administration. Sustained IGF-1 elevation may become measurable within several days, with cumulative effects developing over two to four weeks of repeated exposure.

No. CJC-1295 DAC is a growth hormone-releasing hormone (GHRH) analog rather than synthetic human growth hormone (HGH). It stimulates the pituitary gland to release endogenous growth hormone instead of supplying HGH directly.

Many researchers investigate combinations with GHRP-class peptides such as Ipamorelin or GHRP-6 to evaluate synergistic activation of growth hormone release through both GHRH and ghrelin receptor signaling pathways.

Regulations vary by country. In the United States, CJC-1295 DAC is generally sold for laboratory research purposes only and is not intended for human consumption. Availability may be limited to qualified researchers and licensed facilities.

Lyophilized powder should be stored refrigerated at 2–8°C and protected from direct light. After reconstitution with bacteriostatic water, the solution should remain refrigerated and is commonly used within 30 days according to research protocols.

Dragon Pharma CJC-1295 DAC features verified peptide sequence integrity, HPLC-confirmed purity, and accurately dosed lyophilized peptide powder manufactured to consistent quality standards for research applications.

For laboratory preparation, bacteriostatic water is typically introduced slowly along the inside wall of the vial to minimize foaming. The vial should be gently swirled until dissolved rather than shaken vigorously.

Because CJC-1295 DAC is a non-androgenic peptide that stimulates endogenous endocrine pathways rather than supplying anabolic hormones, traditional post-cycle therapy (PCT) is generally not associated with research involving this compound.